(SVRA) Savara - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8051111016
SVRA: Respiratory, Pulmonary, Proteinosis, Autoimmune, Inhaled, Treatment
Savara Inc. (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company specializing in the development of therapies for rare respiratory diseases. The companys lead product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) currently in Phase 3 clinical trials for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), a rare and life-threatening lung disorder. Savara is headquartered in Langhorne, Pennsylvania, and focuses on addressing unmet medical needs in pulmonary diseases. Web URL: https://www.savarapharma.com.
Based on the provided data, here is a 3-month forecast for Savara Inc. (SVRA):
Additional Sources for SVRA Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
SVRA Stock Overview
Market Cap in USD | 527m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2017-06-01 |
SVRA Stock Ratings
Growth Rating | 14.4 |
Fundamental | - |
Dividend Rating | 0.0 |
Rel. Strength | -26.3 |
Analysts | 4.38/5 |
Fair Price Momentum | 2.87 USD |
Fair Price DCF | - |
SVRA Dividends
No Dividends PaidSVRA Growth Ratios
Growth Correlation 3m | 51.2% |
Growth Correlation 12m | -87.4% |
Growth Correlation 5y | 69.5% |
CAGR 5y | 7.23% |
CAGR/Max DD 5y | 0.11 |
Sharpe Ratio 12m | -1.30 |
Alpha | -38.68 |
Beta | 0.886 |
Volatility | 55.32% |
Current Volume | 373.6k |
Average Volume 20d | 606.4k |
As of April 30, 2025, the stock is trading at USD 3.26 with a total of 373,559 shares traded.
Over the past week, the price has changed by +1.24%, over one month by +17.69%, over three months by +22.10% and over the past year by -29.28%.
Neither. Based on ValueRay Analyses, Savara is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 14.41 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SVRA as of April 2025 is 2.87. This means that SVRA is currently overvalued and has a potential downside of -11.96%.
Savara has received a consensus analysts rating of 4.38. Therefor, it is recommend to buy SVRA.
- Strong Buy: 4
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, SVRA Savara will be worth about 3.2 in April 2026. The stock is currently trading at 3.26. This means that the stock has a potential downside of -1.23%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 9.4 | 189.6% |
Analysts Target Price | 9.6 | 193.3% |
ValueRay Target Price | 3.2 | -1.2% |